Publications
371
Citations
11,347
Est. group size
~10
Recurring co-author estimate
Active years
39
Publishing since 1988
Typically publishes in teams of ~13 · 4% small-team papers (≤3 authors) · across 22 venues
- Data from Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using <i>UGT1A1</i> Genotype–Guided Dosing
2026
- Supplemental File from Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using <i>UGT1A1</i> Genotype–Guided Dosing
2026
- Perioperative versus adjuvant therapy in resectable pancreas cancer.
Journal of Clinical Oncology · 2025
- PARP inhibitor therapy in patients with <i>IDH1</i> mutated cholangiocarcinoma
The Oncologist · 2024
- BilT03: Phase 1b/2 multicenter trial of nivolumab with 5-fluorouracil and liposomal irinotecan for previously treated advanced biliary tract cancer
Med · 2024
- A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma
European Journal of Cancer · 2024
- Characterization of undifferentiated carcinomas of the pancreas with and without osteoclast-like giant cells
JNCI Cancer Spectrum · 2024
- Phase 1b/2 results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- devimistat as first-line therapy for patients with advanced biliary tract cancer (BilT-04).
Journal of Clinical Oncology · 2024
- Abstract C013: Analysis of tumor immune microenvironment and clinical outcomes in undifferentiated pancreatic carcinomas with and without osteoclast-like giant cells
Cancer Research · 2024
- Tumor immune microenvironment of KRAS G12C mutated pancreatic cancer as compared to other mutations and non-cancer pancreata.
Journal of Clinical Oncology · 2024
- Genomics driven precision oncology in advanced biliary tract cancer improves survival
Neoplasia · 2023
- Survival Analysis of 1140 Patients with Biliary Cancer and Benefit from Concurrent Renin-Angiotensin Antagonists, Statins, or Aspirin with Systemic Therapy
The Oncologist · 2023
- 1625P Multicenter, randomized, parallel group, phase II study to establish the efficacy and safety of CBP501, cisplatin, and nivolumab for ≥ third-line treatment of patients with exocrine pancreatic cancer and WBC <10,000/mm3
Annals of Oncology · 2023
- Updated results of a phase 1 study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC; SGNS40-001).
Journal of Clinical Oncology · 2023
- Phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy following first-line platinum-based chemotherapy in patients with advanced biliary tract cancer (BTC): BilT-02.
Journal of Clinical Oncology · 2023
- Journal of Clinical Oncology×38
- Annals of Oncology×8
- Cancer Research×5
- Clinical Cancer Research×3
- JAMA Oncology×2
- G. Martel
Medicine · The Ohio State University
- Bas Groot Koerkamp
Medicine · The Ohio State University
- Ayman El Nakeeb
Medicine · Indiana University
- Jordan M. Cloyd
Medicine · The Ohio State University
- Matthew J. Weiss
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile